Hugel’s botulinus toxin medication, Botulax (Letybo), has proved to be effective in improving furrows between eyebrows through phase 3 clinical trials in the U.S. and Europe, the company said Tuesday.

It added that the trial results were published in the June issue of Aesthetic Surgery Journal.

According to the company, 94 percent of patients showed improvement in glabella wrinkles four weeks after taking the drug, and the effect lasted for about four months. The median value for the revelation of effect was three days, and worry lines decreased 24 hours after administration in about 25 percent of patients.

Hugel said that wrinkles nearly faded or disappeared four weeks after injections in 48.5 percent of patients with thick glabella wrinkles and proved to be constantly effective, drug-fast, and safe even with repeated doses for 12 months.

Phase 3 clinical trial evaluated the drug’s efficacy and safety through a random double-blind placebo-controlled study on 1,200 people.

Hugel speeds up efforts to expand business in Europe based on such trial results. The company has won approvals from 11 countries, including the U.K, France, Germany, Italy, and Spain, after scoring a nod for Botulax from Europe’s Heads of Medicines Agencies (HMA) in January.

“Botulax have received trust from customers and medical workers based on its proven quality, efficacy, and safety, achieving first place in the Korean market and expanding overseas business in over 40 countries. We are glad to prove Botulax’s competency again through a global academic journal,” a Hugel official. “We aim to expand overseas market and introduce Botulax’s differentiated value based on fact-based marketing.”